Edgewise Therapeutics, Inc. (EWTX)
Oxford Ledge is still expanding full research coverage of EWTX. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Edgewise develops small molecule medicines for serious muscle diseases using a muscle-focused drug discovery platform, with lead programs in muscular dystrophies and cardiac conditions.
SEC filings
- 8-K Completion of acquisition or disposition; Regulation FD disclosure; Financial statements and exhibits 2026-07-13
- 8-K Shareholder vote results 2026-06-05
- 8-K Entry into material agreement; Financial statements and exhibits 2026-06-01
- 8-K Results of operations / financial condition; Financial statements and exhibits 2026-05-07
- 10-Q Quarterly financial report (unaudited) 2026-05-07
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for EWTX. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open EWTX in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.